Atopic Keratoconjunctivitis

Atopic Background

AKC occurs almost exclusively in individuals with atopic dermatitis (AD), occurring in approximately 25–40% of AD patients. It is part of the atopic triad (AD, allergic rhinitis, asthma) and shares the same underlying dysregulated immune architecture. The term “atopy” describes a genetic predisposition to IgE-mediated hypersensitivity responses to common environmental antigens.

Genetic Predisposition

• Filaggrin (FLG) gene mutations: Loss-of-function mutations in FLG — encoding the epidermal barrier protein filaggrin — are the strongest identified genetic risk factor for AD and AKC. Filaggrin deficiency impairs the skin and mucosal barrier, facilitating allergen sensitisation
• HLA associations: HLA-DR and HLA-DQ polymorphisms have been linked to AKC susceptibility and severity in several populations
• Cytokine gene polymorphisms: Variants in IL-4, IL-13, IL-31, and TSLP (thymic stromal lymphopoietin) genes alter Th2 cytokine signalling and predispose to atopic disease
• Family history: First-degree relatives with atopic disease confer 2–3× increased risk; concordance rates in monozygotic twins reach 70–80% for AD

Triggering Allergens and Environmental Factors

• House dust mite (Dermatophagoides pteronyssinus / farinae): The most prevalent sensitising allergen in AKC; perennial exposure perpetuates chronic inflammation
• Pet dander: Fel d 1 (cat) and Can f 1 (dog) are potent sensitisers in genetically predisposed individuals
• Pollens: Grass, tree, and weed pollens may trigger or exacerbate AKC, though seasonal variation is less pronounced than in seasonal allergic conjunctivitis
• Mould spores: Aspergillus and Alternaria species; particularly relevant in humid climates
• Staphylococcus aureus colonisation: S. aureus colonises the periocular skin and lid margin in up to 67–90% of AKC patients; staphylococcal exotoxins act as superantigens activating T-cells and amplifying the inflammatory cascade independent of allergen-specific IgE
• Contact allergens: Topical eye drop preservatives (benzalkonium chloride), cosmetics, and nickel may provoke a superimposed type IV hypersensitivity component

Dual-Phase Allergic Response

1. Sensitisation: Antigen-presenting cells (dendritic cells, Langerhans cells) in the conjunctival epithelium process allergens and present them to naïve CD4+ T-cells, driving differentiation toward the Th2 phenotype. Th2 cells produce IL-4 and IL-13, promoting B-cell class switching to IgE production. Allergen-specific IgE binds to high-affinity FcεRI receptors on mast cells and basophils in the conjunctival stroma
2. Early phase (Type I, IgE-mediated): Re-exposure to allergen cross-links surface IgE on sensitised mast cells, triggering immediate degranulation. Released mediators include histamine (pruritus, vasodilation), tryptase, prostaglandin D2, leukotriene C4/D4/E4 (chemotaxis, vascular permeability), and platelet-activating factor. Onset occurs within minutes; produces acute itching and watering
3. Late phase (4–24 hours): Cytokines and chemokines produced during the early phase (IL-5, eotaxin, RANTES) recruit eosinophils, basophils, and neutrophils. Eosinophils are particularly destructive: major basic protein (MBP), eosinophil cationic protein (ECP), and eosinophil-derived neurotoxin (EDN) directly damage corneal epithelial cells and conjunctival stroma
4. Chronic inflammation (Type IV, T-cell–mediated): In AKC, the late-phase response gives way to a sustained Th2-dominated chronic inflammatory state with additional Th1 and Th17 contributions. Persistent T-cell activation, mast cell hyperplasia, and subepithelial fibrosis characterise this phase. TGF-β and IL-13 drive conjunctival fibroblast activation and collagen deposition, producing the cicatricial changes that distinguish AKC from other ocular allergic conditions

Corneal Pathomechanism

Corneal involvement in AKC arises from several mechanisms: (1) direct cytotoxic damage by eosinophil granule proteins (MBP, ECP) deposited in the epithelial basement membrane zone; (2) limbal stem cell deficiency secondary to chronic limbal inflammation and cicatrisation, impairs corneal re-epithelialisation; (3) secondary Staphylococcus aureus keratitis and marginal infiltrates due to colonisation of the compromised lid margin; (4) neurotrophic keratopathy from chronic inflammation of corneal nerves; and (5) corneal neovascularisation driven by VEGF released by activated mast cells and macrophages, violating the avascular corneal privilege. Over time, stromal scarring, subepithelial fibrosis, and vascularisation produce irreversible central corneal opacity.

Role of Staphylococcal Superantigens

Staphylococcal enterotoxins (SEA, SEB) and toxic shock syndrome toxin-1 (TSST-1) function as superantigens, bypassing normal antigen presentation to directly activate up to 20% of the T-cell repertoire. This produces massive cytokine release (IL-2, IFN-γ, TNF-α), amplifying the ocular surface inflammatory burden independently of allergen-specific IgE. Superantigen-specific IgE has also been detected in AKC patients, suggesting an additional IgE-mediated component to bacterial-driven flares.

By Severity (Foster–Calonge Grading)

By Anatomical Involvement

• Eyelid-predominant AKC: Prominent eczematous lid margin disease, blepharitis, Staphylococcus colonisation with relative conjunctival sparing in early disease
• Conjunctival-predominant AKC: Marked papillary reaction, chemosis, mucoid discharge; lid skin less involved
• Corneolimbal AKC: Significant corneal involvement with PEE, neovascularisation, or limbal inflammation (Trantas dots); highest risk for visual loss
• Cicatricial AKC: Dominated by subconjunctival fibrosis and forniceal shortening; overlap with mucous membrane pemphigoid in differential

Comparison with Other Ocular Allergic Diseases

Established Risk Factors

• Atopic dermatitis (essential): AKC almost invariably occurs in the context of moderate-to-severe AD; disease severity of AD correlates with AKC severity
• Male sex: Male-to-female ratio approximately 2:1 to 3:1; reasons not fully elucidated but may reflect sex-linked differences in immune regulation
• Family history of atopy: Positive family history in first-degree relatives significantly increases risk
• FLG (filaggrin) mutations: Heterozygous and homozygous carriers have markedly elevated AKC risk; FLG mutations are present in approximately 50% of European AD patients
• Elevated total serum IgE: Total IgE >100 IU/mL is common; levels above 1000 IU/mL are frequently seen in severe AKC
• Polysensitisation: Sensitisation to multiple aeroallergens — particularly house dust mite and pet dander — increases ocular disease burden

Factors Associated with Increased Severity

• Staphylococcus aureus lid colonisation: High bacterial load on the lid margin amplifies inflammation via superantigen pathway and predisposes to secondary keratitis
• Contact lens wear: Exacerbates mechanical irritation and hypoxia; increases risk of keratoconus progression; generally contraindicated in active AKC
• Eye rubbing: Chronic vigorous eye rubbing — driven by intense pruritus — damages the corneal epithelium, promotes keratoconus, and introduces new antigens from periocular skin
• Topical steroid exposure: Prolonged or inappropriate corticosteroid use risks cataract, glaucoma, and herpetic reactivation
• Herpes simplex virus (HSV) co-infection: Atopic individuals have impaired innate anti-viral immunity (eczema herpeticum); HSV keratitis in AKC carries a high risk of corneal scarring and may be misattributed to the underlying condition
• Keratoconus: AKC is a recognised risk factor for keratoconus development, likely driven by chronic eye rubbing and corneal weakening by eosinophil-derived proteases

Eyelid and Periocular Signs

• Eczematous eyelid skin: Erythematous, lichenified, scaly, or crusted skin of the upper and lower eyelids; periocular hyperpigmentation from chronic rubbing (post-inflammatory); fissuring at the lateral canthi
• Madarosis: Loss of eyelashes from chronic lid margin inflammation and mechanical rubbing; can be partial or complete
• Blepharitis: Anterior (Staphylococcal) and posterior (meibomian gland dysfunction) blepharitis are common; lid margin hyperaemia, crusting, and telangiectasia
• Dennie–Morgan infraorbital folds: Infraorbital skin folds characteristic of atopic individuals; double skin crease below the lower eyelid
• Hertoghe sign: Thinning or absence of the lateral third of the eyebrow from chronic rubbing
• Eyelid thickening and ptosis: Chronic oedema and infiltration may produce mechanical ptosis in severe cases

Conjunctival Signs

• Papillary reaction: Fine-to-giant papillae on the upper and lower tarsal conjunctiva; unlike VKC (predominantly upper tarsal), AKC has more frequent bilateral and lower tarsal involvement
• Conjunctival hyperaemia: Diffuse injection of bulbar and palpebral conjunctiva; chemosis may be present during acute flares
• Mucoid discharge: Stringy, white-to-grey mucoid discharge; differs from purulent discharge of bacterial conjunctivitis
• Subconjunctival fibrosis: White fibrous lines or sheets in the substantia propria; visible on slit lamp as pale subepithelial bands; heralds progression to cicatricial disease
• Forniceal shortening and symblepharon: Progressive cicatrisation obliterates the inferior and superior fornices; adhesions between palpebral and bulbar conjunctiva (symblepharon) develop in advanced disease
• Trantas dots: Whitish accumulations of eosinophils and degenerate epithelial cells at the superior limbus; more commonly associated with VKC but can occur in AKC

Corneal Signs

• Punctate epithelial erosions (PEE): Diffuse or inferior PEE on fluorescein staining; earliest corneal manifestation
• Persistent epithelial defects (PED): Failure of re-epithelialisation due to limbal stem cell damage and neurotrophic changes
• Superficial corneal neovascularisation (pannus): Vascular ingrowth from the superior limbus initially; extends centrally in severe disease; compromises optical clarity
• Subepithelial scarring and opacification: Grey-white stromal haze from repeated epithelial damage and subsequent fibrosis; can cause significant visual impairment
• Shield ulcer: Less common than in VKC but can occur; oval epithelial defect in the superior cornea from large papillae mechanically abrading the epithelium
• Keratoconus: Progressive inferior corneal thinning and ectasia, detectable on corneal topography (Pentacam/Orbscan); incidence in AKC is significantly elevated above the general population
• Limbal stem cell deficiency (LSCD): Vascularisation and conjunctivalisation of the corneal surface; central pannus with loss of Palisades of Vogt; in severe cases leads to total LSCD and corneal blindness

Primary Ocular Symptoms

• Intense, chronic pruritus: The cardinal symptom; persistent, often debilitating itching that drives repetitive eye rubbing; worsened by allergen exposure, dry environments, and stress
• Burning and foreign body sensation: Constant discomfort reflecting ocular surface damage and tear film instability; often worse than in other allergic conjunctivitides due to corneal involvement
• Lacrimation (watering): Reflex tearing from ocular surface irritation; may be accompanied by photophobia when the cornea is involved
• Photophobia: Light sensitivity; indicates corneal involvement (PEE, ulcer, scarring) and should prompt urgent slit lamp assessment
• Blurred or reduced vision: May result from corneal scarring, irregular astigmatism (keratoconus), cataract, or mucoid discharge obscuring the visual axis; any new visual reduction warrants urgent assessment
• Mucoid discharge: Stringy or ropy mucous discharge, often worse in the morning; patients may report “sticky eyes” upon waking

Associated Systemic Symptoms

• Skin pruritus and eczema flares: Ocular exacerbations frequently parallel worsening of systemic atopic dermatitis
• Nasal congestion, sneezing, rhinorrhoea: Concurrent allergic rhinitis; 90% of AKC patients have concomitant rhinitis
• Wheeze and dyspnoea: Asthma co-exists in approximately 30–40% of atopic patients; atopic march pattern is common
• Sleep disturbance: Nocturnal pruritus (both skin and ocular) significantly impairs quality of life and sleep architecture

Sight-Threatening Ocular Complications

• Corneal scarring and opacification: Progressive subepithelial and stromal fibrosis from recurrent epithelial breakdown; central opacification produces irreversible vision loss; the leading cause of blindness in AKC
• Limbal stem cell deficiency (LSCD): Loss of the regenerative limbal epithelial stem cell niche from chronic limbal inflammation; results in conjunctivalisation of the corneal surface, vascularisation, and recurrent epithelial instability
• Keratoconus: Occurs in up to 16–29% of AKC patients; progressive corneal ectasia leading to irregular myopic astigmatism; contact lens intolerance; advanced cases may require corneal collagen cross-linking or keratoplasty
• Herpetic keratitis (HSV): Atopic individuals have impaired innate anti-viral immunity; HSV reactivation in the cornea can mimic AKC flares; may lead to stromal scarring, disciform keratitis, or neurotrophic ulceration
• Bacterial keratitis: Secondary to chronic lid colonisation with S. aureus, disrupted corneal epithelium, and chronic steroid use; Pseudomonas and MRSA are also relevant organisms
• Persistent corneal epithelial defects: Non-healing epithelial defects from neurotrophic keratopathy, LSCD, or secondary infection; risk of sterile melting and perforation in severe cases

Structural and Treatment-Related Complications

• Atopic cataract: AKC patients develop a characteristic “shield cataract” — anterior subcapsular opacity with a stellate morphology — and also posterior subcapsular cataracts (from chronic topical and systemic steroid use). Prevalence of cataract in AKC is significantly elevated, with rates up to 10× higher than in the general population of comparable age
• Glaucoma: Steroid-induced ocular hypertension and open-angle glaucoma are complications of chronic topical corticosteroid therapy; requires regular IOP monitoring
• Cicatricial conjunctival changes: Symblepharon, forniceal obliteration, and ankyloblepharon in end-stage disease; may restrict ocular motility and preclude surgical approaches
• Retinal detachment: Atopic patients have a recognised increased risk of rhegmatogenous retinal detachment (RD); incidence is 3–8× the general population. Proposed mechanisms include vitreous traction from chronic rubbing, structural vitreoretinal anomalies associated with atopy, and secondary to atopic cataract surgery

Atopic Dermatitis (Eczema)

Atopic dermatitis is the universal systemic association in AKC. Ocular disease severity correlates with skin disease severity: patients with moderate-to-severe AD are at highest risk for corneal complications. The SCORAD (SCORing Atopic Dermatitis) index has been used to track this correlation. Facial and periocular AD involvement — erythema, lichenification, and fissuring — directly compromises the eyelid skin barrier and provides a reservoir of Staphylococcal colonisation that perpetuates ocular surface inflammation.

Atopic March and Comorbidities

• Allergic rhinitis: Present in up to 90% of AKC patients; shares aeroallergen sensitisation profile; nasobronchial–ocular reflex can amplify ocular symptoms through neural and humoral pathways
• Asthma: Affects approximately 30–40% of AD patients; both asthma and AKC involve Th2-mediated eosinophilic inflammation of mucosal surfaces; poorly controlled asthma correlates with worse ocular disease in some studies
• Food allergies: IgE-mediated food hypersensitivity (peanut, tree nuts, egg, milk) is more prevalent in AD; systemic reactions can exacerbate ocular surface inflammation
• Eczema herpeticum (Kaposi’s varicelliform eruption): Disseminated HSV-1 infection superimposed on areas of active AD; a dermatological emergency. The same impaired anti-viral innate immunity predisposes to HSV keratitis and can result in bilateral corneal disease if the ocular surface is involved during an eczema herpeticum episode

Systemic Complications of Ocular Treatments

• Systemic corticosteroids: Long-term oral prednisolone (used for severe AKC) produces HPA axis suppression, osteoporosis, diabetes, hypertension, and immune suppression with increased infection risk
• Ciclosporin A (systemic): Nephrotoxicity and hypertension require regular monitoring of renal function and blood pressure
• Dupilumab (IL-4/IL-13 antagonist): The biologic agent used for moderate-to-severe AD may paradoxically cause or worsen conjunctivitis in some patients (dupilumab-associated conjunctivitis), necessitating concurrent topical treatment

Clinical Diagnosis

The diagnosis of AKC is primarily clinical, based on the triad of: (1) personal or family history of atopic disease (atopic dermatitis, asthma, allergic rhinitis); (2) characteristic ocular findings; and (3) exclusion of other causes of chronic conjunctivitis. No single pathognomonic test exists; diagnosis requires synthesis of history, external examination, and slit lamp findings.

History

• Duration and chronicity of ocular symptoms (typically >1 year, perennial)
• History of atopic dermatitis — age of onset, current skin disease activity, topical steroid use
• Concurrent allergic rhinitis, asthma, or food allergies
• Family history of atopic disease
• Identified allergen triggers and seasonal variation
• History of herpetic disease (cold sores, eczema herpeticum)
• Contact lens history — type, wearing schedule, compliance
• Current and prior topical medications (including preservative-containing drops)

Clinical Examination

Laboratory and Ancillary Investigations

• Total serum IgE: Typically elevated (>100 IU/mL); very high levels (>1000 IU/mL) associated with severe AKC; useful to support the atopic diagnosis but not diagnostic of AKC alone
• Allergen-specific IgE (RAST / ImmunoCAP): Identifies sensitising allergens (house dust mite, cat, dog dander, pollens); guides allergen avoidance and immunotherapy decisions
• Skin prick testing (SPT): Performed by allergist; confirms IgE-mediated sensitisation; should be done in consultation with an allergist or immunologist
• Conjunctival cytology / scraping: Eosinophils on Giemsa-stained conjunctival scraping support allergic aetiology; not routinely required but useful in diagnostically uncertain cases
• Eyelid/conjunctival swab culture: For S. aureus and MRSA identification; indicated when secondary bacterial keratitis is suspected or to guide targeted antibiotic therapy
• Corneal confocal microscopy: Allows in-vivo assessment of corneal nerve density, keratocyte activation, and inflammatory cell infiltration; a research tool with emerging clinical applications in AKC
• Tear cytokine / mediator analysis: Elevated IL-4, IL-13, IL-5, eotaxin, tryptase, and total IgE in tear fluid support the diagnosis; primarily research-based at present

Overall Prognosis

AKC is a chronic, lifelong condition characterised by a relapsing-remitting course. Unlike vernal keratoconjunctivitis — which tends to remit spontaneously in the second to third decade — AKC often persists into middle age and beyond, mirroring the persistence of atopic dermatitis in adults. With appropriate long-term management, the majority of patients achieve adequate disease control, but complete remission is uncommon. Visual prognosis is strongly dependent on the degree of corneal involvement at presentation and the effectiveness of early intervention. Patients with corneal scarring or LSCD identified early and managed aggressively have a significantly better visual outcome than those presenting late.

Prognostic Factors

Quality of Life Impact

AKC significantly impairs quality of life across multiple domains. Chronic ocular pruritus and sleep disturbance affect concentration and productivity. Vision loss from corneal complications has profound occupational and psychosocial consequences. Patients with concurrent severe AD carry an additional burden of skin disease, body image concerns, and systemic comorbidities. Multidisciplinary management — involving ophthalmology, dermatology, and allergy/immunology — is associated with improved patient-reported outcomes.